Bindee Kuriya

Jun 4, 2024 | acrjournals.onlinelibrary.wiley.com | Holland Bone |Bindee Kuriya |Gillian A. Hawker |Lihi Eder

INTRODUCTION Treating patients with gout to a target serum uric acid (SUA) level of <360 μmol/L or 6 mg/dL (ie, treatment to target [T2T]) using urate-lowering therapy (ULT) has been associated with decreased flares, reductions in tophi, and improved quality of life.1-5 As such, this approach has been endorsed in the 2020 American College of Rheumatology (ACR) and 2016 EULAR guidelines.6, 7 Additionally, a timeframe of 12 months has been recommended within the ACR's electronic clinical...

Jan 1, 2024 | jrheum.org | Timothy Kwok |Bindee Kuriya |Lihi Eder |Vivian Aghanya

To the Editor:Individuals with rheumatoid arthritis (RA) may be at increased risk of severe coronavirus disease 2019 (COVID-19) outcomes.1 Nirmatrelvir/ritonavir has been shown to reduce the risk for hospitalization and death among patients with COVID-19 at risk for progression to severe disease.2 On April 4, 2022, nirmatrelvir/ritonavir became available in Ontario, Canada, for high-risk individuals, including immunosuppressed patients with rheumatic disease, such as RA.

Jul 1, 2023 | jrheum.org | Timothy Kwok |Bindee Kuriya |Lauren King |Lihi Eder

DISCUSSIONIn this population-based study evaluating all contacts with rheumatologists before and during the pandemic, there was a significant uptake in telemedicine visits and a precipitous drop of in-person outpatient visits when pandemic measures were imposed in Ontario. Although there was a steady increase in the return to outpatient visits following the pandemic onset, there was sustained use of telemedicine in rheumatology throughout the second year of the pandemic.